The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating（harmful） HER2 mutations or with HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive.
Solid Tumor|HER2 Gene Mutation|HER-2 Gene Amplification|HER-2 Protein Overexpression
DRUG: Pyrotinib
Objective Response Rate, Objective response rate defined as the patients confirmed complete response or partial response under RECIST 1.0 criteria., at least 3 months
Progression free survival, Progression-free survival estimated using Kaplan-Meier methods is defined as the time from registration to the earlier of death or disease progression, up to 24 months|Duration of Response, The first evaluation of treatment efficacy is the time fromcomplete response or partial response to the first assessment of disease progression or death from any cause., up to 24 months|Disease Control Rate, Objective response rate defined as the patients confirmed complete response or partial response or stable disease under RECIST 1.0 criteria., up to 24 months|Overall Survival, Overall survival estimated using Kaplan-Meier methods is defined as the time from treatment initiation to death by any cause, up to 36 months|Safety (Adverse Events and Serious Adverse Events), From consent through 28 days following treatment completion (estimated 6 months), up to 36 months
This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating（harmful） HER2 mutations or with HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive.